Elanco, the animal health division of global pharmaceutical company Eli Lilly & Co, has launched an enhanced business operation in Ireland, overseen by UK and Ireland director Gaynor Hillier.
The company says the move follows Elanco’s acquisitions last year of Novartis Animal Health and Lohmann Animal Health, both of which are now fully integrated into the Elanco business. This will help the business grow within the Irish agriculture and companion animal sectors, as in its international operations.
Ms Hillier notes that Elanco has traditionally been strong in the pig and poultry sectors of the animal health industry, but the addition of the Novartis and Lohmann portfolios mean it is now a serious player in the ruminant and pet animal markets.
“Elanco has a 60-year track record in delivering effective veterinary pharmaceutical solutions for veterinarians, farmers and pet lovers, and we want to build on this for the future,” stated Ms Hillier at the formal launch of Irish operation, which will be managed from the UK headquarters at Basingstoke.
“Over the past number of years, we have put in a place a clear strategy for acquisition, which has allowed us to build on our core competencies. Driving innovation is at the very heart of the Elanco business model. In achieving this, we have been able to offer our customers new solutions to the myriad health and welfare concerns that impact on farmers and pet enthusiasts.”
“But investing in the brands of today is only a small part of our vision for the future,” she continued. “The Novartis and Lohmann deals will allow Elanco’s R&D capabilities to expand significantly, from both a facilities and people point of view. We are now able to tap into a much enhanced pool of research talent with a proven ability to deliver new and embracing animal health solutions. All of this is good news for practising veterinarians, livestock farmers and pet owners throughout Ireland.”
For food animals, Elanco’s R&D priorities include protection from disease; reducing the environmental impact of livestock production; increasing nutrient digestibility; enhancing animal well-being and eradicating food borne illnesses.
“The launch of the new Elanco business in Ireland represents a very positive dynamic from an animal health, welfare and disease prevention perspective,” Ms Hillier concludes. “But this is only the start. Elanco is now an unmatched resource in terms of developing innovative solutions which meet the challenge of improving and animal health and welfare standards. Our aim is to convert all of this potential into new and cutting edge products in short order.”
Elanco has a veterinary vaccine factory at Sligo in the Republic, from where it supplies much of Europe with vaccine products.